Brandsymbol’s Post

Neuraxpharm Group (Neuraxpharm) and Pharmathen have announced a strategic alliance to co-develop new long-acting injectable therapies within the psychiatry field under Pharmathen’s long-acting therapeutic technologies (LATT) program. https://lnkd.in/e85Emt9S #injectables #alliance #pharma

📢 New Medical Breakthrough! Dr. David Saperstein, in collaboration with esteemed colleagues, has co-authored a landmark publication in Frontiers in Neurology, redefining how we understand and treat Postural Orthostatic Tachycardia Syndrome (POTS) and other autonomic disorders. This work challenges misconceptions that often lead to misdiagnosis, distinguishing these conditions from Functional Neurologic Disorders (FND) with evidence-based clarity. This publication comes at a pivotal time when autonomic disorders are increasingly misdiagnosed, particularly in the context of Long COVID. Dr. Saperstein and co-authors emphasize the need for accurate diagnostic criteria, ensuring that patients with POTS and other autonomic disorders receive appropriate treatment pathways instead of psychiatric misattributions. 💡 Key Highlights: 🔹Establishes objective criteria for diagnosing autonomic disorders like POTS. 🔹Clarifies the distinction between POTS and FND to guide clinicians in accurate diagnosis and treatment. 🔹Stresses the importance of addressing misdiagnoses that can delay effective therapies for patients. This work promises to reshape perspectives on autonomic disorders and contribute to better care practices globally. The full article will be published soon, advancing our understanding of these complex conditions. Stay tuned for more updates as we continue to advocate for accurate diagnoses and effective treatments. 📚✨ 🔗 Click the link to read the full article. https://lnkd.in/gCNuPWWQ

🌟 Exciting developments in the realm of neuropsychiatry! The newly approved schizophrenia drug Cobenfy, developed by Bristol Myers Squibb (#BMS), has come a long way from its origins as a candidate for Alzheimer's disease at Eli Lilly (#EliLilly). Originally designed to enhance cognitive function, Cobenfy showcases the serendipitous nature of drug development in neuropsychiatry. Its journey highlights the importance of innovation born from unexpected findings. As Andrew Miller, former CEO of Karuna Therapeutics (#Karuna), noted, the evolution of Cobenfy reflects a broader trend in psychiatric treatments, often stemming from surprising connections. With Cobenfy now on the market as the first novel schizophrenia treatment in 35 years, BMS is set to explore its potential beyond schizophrenia, including possible applications for Alzheimer's disease and bipolar disorder. This journey is a testament to the resilience and creativity within the pharmaceutical industry. Stay tuned for more updates on this transformative treatment! #Neuroscience #Pharmaceuticals #MentalHealth #Innovation #DrugDevelopment https://lnkd.in/e_mf-tyF

Endocannabinoid System in Pathological Processes Mechanisms of action begin to be explained and the therapeutic potential grows for treatment in the areas: metabolism, neurology, psychiatry, autoimmune diseases, and oncology. In this context, countless patients, suffering from serious illnesses, now have a concrete alternative to obtain relief from their suffering. On the other hand, despite the broad international prohibition, the remote history of medical, religious and recreational use and current scientific knowledge have demonstrated that the therapeutic potential of cannabis is safe, effective, economical, with fewer side effects than many medications. widely used. Promising results have been observed, but prospective, double-blind clinical studies are still lacking for broad acceptance of the use of cannabis and its derivatives as a therapeutic alternative. With just over 20 years since the discovery of cannabinoid receptors, there is a considerable and growing number of scientific publications relating the therapeutic potential of cannabis and its cannabinoids for various diseases.

We’re excited to announce our partnership with Neuronostics to revolutionize clinical trials with integrated EEG solutions. Together, we are delivering faster, smarter, and more impactful results for pharmaceutical companies, CROs, and academic researchers. This collaboration is a game-changer for neurology and psychiatry research, driving better outcomes for patients worldwide. The future of clinical trials starts now! 🧠 #Partnership #ClinicalTrials #EEG

5/13/24: AbbVie and Gilgamesh Pharmaceuticals | Announce Collaboration and Option-to-License Agreement to Develop Next-Generation Therapies for Psychiatric Disorders Collaboration to leverage AbbVie's psychiatry expertise and Gilgamesh Pharmaceuticals's innovative research platform to develop next-generation neuroplastogens for the treatment of psychiatric disorders https://lnkd.in/g7G4z5c5

Discover Saladax Biomedical Inc., a pioneer in developing and manufacturing rapid, accurate therapeutic drug monitoring (TDM) assays. These tests are designed for essential medications frequently prescribed in psychiatry and oncology, offering personalized dosing solutions to enhance patient care. Their product portfolio includes: 𝐌𝐲𝐂𝐚𝐫𝐞™ 𝐎𝐧𝐜𝐨𝐥𝐨𝐠𝐲: 𝘗𝘳𝘦𝘤𝘪𝘴𝘪𝘰𝘯 𝘵𝘰𝘰𝘭𝘴 𝘧𝘰𝘳 𝘮𝘰𝘯𝘪𝘵𝘰𝘳𝘪𝘯𝘨 𝘢𝘯𝘥 𝘰𝘱𝘵𝘪𝘮𝘪𝘻𝘪𝘯𝘨 𝘰𝘯𝘤𝘰𝘭𝘰𝘨𝘺 𝘵𝘳𝘦𝘢𝘵𝘮𝘦𝘯𝘵𝘴, 𝘦𝘯𝘢𝘣𝘭𝘪𝘯𝘨 𝘣𝘦𝘵𝘵𝘦𝘳 𝘵𝘳𝘦𝘢𝘵𝘮𝘦𝘯𝘵 𝘥𝘦𝘤𝘪𝘴𝘪𝘰𝘯𝘴 𝘸𝘪𝘵𝘩 𝘱𝘦𝘳𝘴𝘰𝘯𝘢𝘭𝘪𝘻𝘦𝘥 𝘢𝘱𝘱𝘳𝘰𝘢𝘤𝘩𝘦𝘴. 𝐌𝐲𝐂𝐚𝐫𝐞™ 𝐏𝐬𝐲𝐜𝐡𝐢𝐚𝐭𝐫𝐲: 𝘊𝘰𝘮𝘱𝘳𝘦𝘩𝘦𝘯𝘴𝘪𝘷𝘦 𝘴𝘰𝘭𝘶𝘵𝘪𝘰𝘯𝘴 𝘵𝘰 𝘦𝘯𝘴𝘶𝘳𝘦 𝘱𝘳𝘰𝘱𝘦𝘳 𝘮𝘦𝘥𝘪𝘤𝘢𝘵𝘪𝘰𝘯 𝘭𝘦𝘷𝘦𝘭𝘴 𝘧𝘰𝘳 𝘪𝘮𝘱𝘳𝘰𝘷𝘦𝘥 𝘮𝘦𝘯𝘵𝘢𝘭 𝘩𝘦𝘢𝘭𝘵𝘩 𝘮𝘢𝘯𝘢𝘨𝘦𝘮𝘦𝘯𝘵. With Saladax’s revolutionary products, healthcare providers can deliver better outcomes, reduce adverse effects, and personalize treatment plans. For more information about Saladax Biomedical’s products or to learn how they can benefit your practice, feel free to connect with us today! #HealthcareInnovation #Diagnostics #TherapeuticDrugMonitoring #Oncology #PersonalizedMedicine #𝐏𝐬𝐲𝐜𝐡𝐢𝐚𝐭𝐫𝐲

In the search for new models to enhance precision in drug development in Psychiatry, Clexio Biosciences is proud to have collaborated with NeuroKaire (formerly Genetika+) to explore the utility of NeuroKaire’s biomarker for profiling the efficacy of antidepressant compounds. The findings were presented in a poster at the #CNSSummit.   This approach was used to assess CLE-100's (parent and metabolite) effect on synaptic plasticity in iPSC-derived neurons, from individual well-characterized depressed patients.   CLE-100 is an investigational drug and is currently not approved for commercial distribution. For a look at the full poster, click: https://lnkd.in/dabt-tqe   For more information on Clexio please visit our website: www.clexio.com   #depression #MDD #CLE-100 #esketamine #CNSSummit 

We're excited to announce our next #Dementia Academy webinar: System readiness for DMTs in #Alzheimers disease 🗓️ Monday 25th November · 16:00 Speakers: ▸ Prof Iracema Leroi, associate professor in geriatric psychiatry, Trinity College Dublin & Faculty, GBHI ▸ Dr George Crowther, consultant in old age liaison psychiatry, Leeds and York Partnership Foundation Trust New drug treatments with the potential to modify Alzheimer's disease (AD) are becoming available, presenting a challenge for integration into current healthcare systems. Understanding public attitudes toward these therapies is crucial. During this webinar, we will explore public perceptions of disease-modifying therapies (DMTs) for AD, including awareness of prevention and treatment options, perceived benefits and risks, and willingness to pay (WTP). We outline how to ascertain numbers of potential eligible patients for DMTs, the key components needed to ensure a health system is prepared to deliver these treatments, and insights into both public and patient acceptance of the therapies. Sign up now to join the live webinar: https://lnkd.in/ekP6fqY5

The potential for GLP-1 receptor agonists to help with alcohol use disorders has emerged from various observations and preliminary studies: 1. Anecdotal Reports: Many of my patients taking GLP-1 RAs like semaglutide (Ozempic, Wegovy, Rybelsus) have reported unintended reductions in alcohol consumption. 2. Social Media Reports: Reports often come from social media and other informal sources, indicating a potential link between GLP-1 RAs and decreased alcohol use. 3. Preclinical Studies: Animal studies have shown that GLP-1 RAs can reduce alcohol intake. For instance, research on rodents has demonstrated that GLP-1 receptor stimulation can decrease alcohol consumption and seeking behavior, suggesting a possible effect on alcohol-related neural pathways. 4. Mechanistic Insights: GLP-1 receptors are located in brain regions associated with reward and addiction, such as the nucleus accumbens. Activation of these receptors may influence the neurobiological processes underlying addiction, including satiety, craving, and aversion. 5. Clinical Observations: Some clinicians have noted reduced alcohol consumption in patients being treated with GLP-1 RAs for diabetes or obesity, leading to further interest in these medications for alcohol use disorder treatment. 6. Ongoing Clinical Trials: There are now clinical trials underway specifically investigating the effects of GLP-1 RAs on alcohol use disorders. These trials aim to provide more rigorous evidence and understand the underlying mechanisms. 7. Potential Neurobehavioral Mechanisms: The observed reductions in alcohol use may be due to several neurobehavioral mechanisms influenced by GLP-1 RAs, such as altered reward processing, reduced craving and preoccupation with alcohol, enhanced satiety, and changes in subjective responses to alcohol. Stay tuned! GLP RA's may be the next revolutionary medication for Psychiatry! #GLP1ReceptorAgonists #AlcoholUseDisorder #Semaglutide #Ozempic #Wegovy #Rybelsus #AddictionTreatment #Pharmacovigilance #DrugRepurposing #MentalHealth #Neurobiology #ClinicalResearch #HealthcareInnovation #MedicalScience #PatientCare #AddictionRecovery #HealthTech #MedicalResearch #BehavioralHealth #empathymindcare #empathyminded